Boris L. Zaïtra

Head of Corporate Business Development at Roche

Appears in 1 story

Stories

Roche bets $15 billion on Chinese antibody-drug conjugates

Led negotiation of the Hansoh collaboration

Roche will pay Hansoh Pharmaceutical up to $15 billion for a portfolio of antibody-drug conjugates, cancer drugs that carry a toxin directly to tumor cells. The Swiss drugmaker put $400 million down Monday, with $110 million more due in a year.

Updated 3 hours ago